Answers are grounded in this paper and cite their sources.
We engineered TCR-T cells of desired specificities that transiently escape the immunosuppressive effects of TAC and MMF. This finding has important clinical applications for the treatment of HBV-HCC relapses and other pathologies occurring in organ transplanted patients.
No takes yet. Share an insight, caveat, or question.
Hafezi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: